Sie befinden sich hier: Home > News Medizin
Medizin
ASCO: Eisai präsentiert Daten zu Eribulin und Lenvatinib
Terminhinweise:
Takahashi S et al.
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results
Abstract No: 6088
Poster Presentation:
Head and Neck Cancer
Date: 4 June
Time: 1:00-4:30 PM
Hutson T et al.
Subgroup analyses from the phase 2 trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)
Abstract No: 4553
Poster Presentation:
Genitourinary (Non-prostate) Cancer
Date: 6 June
Time: 1:00-4:30 PM
Chawla S, et al.
Subtype specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open label, randomised study of eribulin (ERI) versus dacarbazine (DTIC) in patients with advanced LPS and leiomyosarcoma (LMS)
Abstract No: 11037
Poster Presentation:
Sarcoma
Date: 6 June
Time: 8:00-11:30 AM
Takahashi S et al.
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results
Abstract No: 6088
Poster Presentation:
Head and Neck Cancer
Date: 4 June
Time: 1:00-4:30 PM
Hutson T et al.
Subgroup analyses from the phase 2 trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC)
Abstract No: 4553
Poster Presentation:
Genitourinary (Non-prostate) Cancer
Date: 6 June
Time: 1:00-4:30 PM
Chawla S, et al.
Subtype specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open label, randomised study of eribulin (ERI) versus dacarbazine (DTIC) in patients with advanced LPS and leiomyosarcoma (LMS)
Abstract No: 11037
Poster Presentation:
Sarcoma
Date: 6 June
Time: 8:00-11:30 AM
Anzeige:
Stichwörter
Das könnte Sie auch interessieren
Sie können folgenden Inhalt einem Kollegen empfehlen:
"ASCO: Eisai präsentiert Daten zu Eribulin und Lenvatinib"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!